About Pulmonary Drug Delivery Systems
Pulmonary delivery of drugs leads to the deposition of drugs in the lungs and subsequent local or systemic therapeutic activity. The pulmonary route of administration for the non-invasive delivery of drugs is mostly preferred because of the large surface area for absorption, high blood circulation, and high permeability rate. Pulmonary drug delivery offers various advantages over peroral routes, such as bypass of hepatic first-pass metabolism, quick onset of action, and low enzymatic activity. Pulmonary delivery of drugs can be achieved by intranasal administration or oral inhalative administration, the latter being more effective. Oral inhalative administration includes intratracheal inhalation and intratracheal instillation. Oral inhalation delivers the aerosolized drug using devices such as MDIs (or pMDIs), PDIs, and nebulizers. Drugs administered by this route are deposited in the respiratory tract via inertial impaction, gravitational sedimentation, and diffusion. The effective delivery of drugs via the pulmonary route requires an optimized combination of drug, its formulation, and device.
TechNavio's analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 8.90 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Pulmonary Drug Delivery Systems market for the period 2015-2019. To calculate the market size, the report considers the revenue from the sales of various pulmonary drug delivery systems intended for oral inhalation including:
• MDIs (or pMDIs)
• DPIs
• Nebulizers
TechNavio's report, the Global Pulmonary Drug Delivery Systems Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Pulmonary Drug Delivery Systems market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Philips Healthcare
Other Prominent Vendors
• 3M Health Care
• Actelion Pharmaceuticals
• Aerogen
• Airon
• Allied Healthcare Products
• Briggs Healthcare
• Carefusion
• Clement Clarke International
• DeVilbiss Healthcare
• Drive Medical Design and Manufacturing
• GF Health Products
• Heyer Medical
• OMRON
• PARI Medical Holding
• Salter Labs
• Teleflex
Market Driver
• Increase in Prevalence and Incidence of Respiratory Diseases
• For a full, detailed list, view our report
Market Challenge
• Intense Market Competition
• For a full, detailed list, view our report
Market Trend
• Increase in Online Marketing Services
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Product Type
08. MDIs
08.1 Introduction
08.2 Basic Components
08.3 Drug Deposition
08.4 Pros and Cons of MDIs
08.5 Market Size and Forecast
09. DPIs
09.1 Introduction
09.2 Segmentation
09.3 Basic Components
09.4 Drug Delivery
09.5 Drug Deposition
09.6 Pros and Cons of DPIs
09.7 Market Size and Forecast
10. Nebulizers
10.1 Introduction
10.2 Pros and Cons of Nebulizers
10.3 Segmentation
10.4 Jet Nebulizers
10.5 Ultrasonic Nebulizers
10.6 Market Size and Forecast
11. Geographical Segmentation
11.1 Pulmonary Drug Delivery Systems Market in Americas
11.1.1 Market Size and Forecast
11.2 Pulmonary Drug Delivery Systems Market in EMEA Region
11.2.1 Market Size and Forecast
11.3 Pulmonary Drug Delivery Systems Market in APAC Region
11.3.1 Market Size and Forecast
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 AstraZeneca
19.2.2 Boehringer Ingelheim
19.2.3 GlaxoSmithKline
19.2.4 Novartis
19.2.5 Philips Healthcare
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 AstraZeneca plc
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation by Revenue 2013
20.1.4 Business Segmentation by Revenue 2011-2013
20.1.5 Sales by Geography
20.1.6 Business Strategy
20.1.7 Key Developments
20.1.8 SWOT Analysis
20.2 Boehringer Ingelheim
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation by Revenue 2013
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Geographical Segmentation by Revenue 2013
20.2.6 Business Strategy
20.2.7 Recent Developments
20.2.8 SWOT Analysis
20.3 GlaxoSmithKline
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation
20.3.4 Business Segmentation by Revenue 2012 and 2013
20.3.5 Sales by Geography
20.3.6 Pipeline Products
20.3.7 Business Strategy
20.3.8 Key Information
20.3.9 SWOT Analysis
20.4 Novartis
20.4.1 Key Facts
20.4.2 Business Description
20.4.3 Business Segmentation
20.4.4 Revenue by Business Segmentation
20.4.5 Revenue Comparison 2012 and 2013
20.4.6 Sales by Geography
20.4.7 Business Strategy
20.4.8 Key Developments
20.4.9 SWOT Analysis
20.5 Philips Healthcare
20.5.1 Key Facts
20.5.2 Business Overview
20.5.3 Revenue by Business Segmentation 2012
20.5.4 Sales by Geography
20.5.5 Business Strategy
20.5.6 Key Developments
20.5.7 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Pulmonary Drug Delivery Systems Market 2014-2019 (US$ billion)
Exhibit 3: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type
Exhibit 4: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type 2014
Exhibit 5: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type 2019
Exhibit 6: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type 2014-2019 (US$ billion)
Exhibit 7: Global Pulmonary Drug Delivery Systems Market Segmentation by Product Type 2014-2019
Exhibit 8: YoY Growth Rate of Global Pulmonary Drug Delivery Systems Market by Product Type 2014-2019
Exhibit 9: Revenue and CAGR of Global Pulmonary Drug Delivery Systems Market by Product Type 2014-2019
Exhibit 10: Metered Dose Inhaler
Exhibit 11: Pros and Cons of MDIs
Exhibit 12: Global MDIs Market 2014-2019 (US$ billion)
Exhibit 13: DPIs Segmentation by Product Type
Exhibit 14: Pros and Cons of DPIs
Exhibit 15: Global DPIs Market 2014-2019 (US$ billion)
Exhibit 16: Pros and Cons of Nebulizers
Exhibit 17: Nebulizers by Product Type
Exhibit 18: Jet Nebulizer
Exhibit 19: Ultrasonic Nebulizer
Exhibit 20: Global Nebulizers Market 2014-2019 (US$ billion)
Exhibit 21: Global Pulmonary Drug Delivery Systems Market Segmentation by Geography 2014
Exhibit 22: Global Pulmonary Drug Delivery Systems Market Segmentation by Geography 2019
Exhibit 23: Global Pulmonary Drug Delivery Systems Market by Geography 2014-2019 (US$ billion)
Exhibit 24: Global Pulmonary Drug Delivery Systems Market by Geography 2014-2019
Exhibit 25: YoY Growth Rate of Global Pulmonary Drug Delivery Systems Market by Geography 2014-2019
Exhibit 26: Revenue and CAGR of Global Pulmonary Drug Delivery Systems Market by Geography 2014-2019
Exhibit 27: Percentage Share of Global Pulmonary Drug Delivery Systems Market by Geography 2014 and 2019
Exhibit 28: Pulmonary Drug Delivery Systems Market in the Americas 2014-2019 (US$ billion)
Exhibit 29: Pulmonary Drug Delivery Systems Market in the EMEA Region 2014-2019 (US$ billion)
Exhibit 30: Pulmonary Drug Delivery Systems Market in EMEA Region by Geography 2014
Exhibit 31: Pulmonary Drug Delivery Systems Market in the APAC Region 2014-2019 (US$ billion)
Exhibit 32: Pulmonary Drug Delivery Systems Market in APAC Region by Geography 2014
Exhibit 33: Pulmicort Sales 2011-2014 (US$ million)
Exhibit 34: Parts of Pulmicort Flexhaler
Exhibit 35: Pulmicort Sales by Geography H1 2014
Exhibit 36: Symbicort Sales 2011-2014 (US$ million)
Exhibit 37: Symbicort Sales by Geography H1 2014
Exhibit 38: Respimat Soft Mist Inhaler
Exhibit 39: Spiriva HandiHaler
Exhibit 40: Parts of Spiriva HandiHaler
Exhibit 41: Spiriva Respimat Cartridge and Parts of Spiriva Respimat Inhaler
Exhibit 42: Spiriva Sales 2011-2014 (US$ million)
Exhibit 43: Combivent Respimat Catridge and Parts of Combivent Respimat
Exhibit 44: Combivent Sales 2011-2014 (US$ million)
Exhibit 45: Berodual Respimat Catridge and Parts of Berodual Respimat Inhaler
Exhibit 46: Ventolin HFA
Exhibit 47: Parts of Ventolin HFA
Exhibit 48: Sales of Ventolin 2011-2014 (US$ million)
Exhibit 49: Sales of Novartis's Pulmonary Delivery Drugs and Devices H1 2014 (US$ million)
Exhibit 50: Arcapta Neohaler
Exhibit 51: Seebri Breezhaler Capsules and Seebri Breezhaler Inhaler
Exhibit 52: Ultibro Breezhaler
Exhibit 53: Tobi Podhaler
Exhibit 54: Tobi Podhaler Blister Pack and Parts of Tobi Podhaler
Exhibit 55: SideStream Nebulizer
Exhibit 56: SideStream Plus
Exhibit 57: InnoSpire Deluxe
Exhibit 58: InnoSpire Elegance
Exhibit 59: InnoSpire Essence
Exhibit 60: I-neb AAD System
Exhibit 61: Parts of I-neb AAD System
Exhibit 62: Sami the Seal
Exhibit 63: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 64: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 65: AstraZeneca plc: Sales by Geography 2013
Exhibit 66: Boehringer Ingelheim: Business Segmentation by Revenue 2013
Exhibit 67: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 68: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
Exhibit 69: GlaxoSmithKline: Business Segmentation 2013
Exhibit 70: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 71: GlaxoSmithKline: Sales by Geography 2013
Exhibit 72: GlaxoSmithKline: Pipeline Products 2013
Exhibit 73: Novartis AG: Business Segmentation
Exhibit 74: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 75: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 76: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 77: Philips Healthcare: Revenue by Business Segmentation 2012
Exhibit 78: Philips Healthcare: Sales by Geography 2012
